ABSTRACT
The monitoring of an adverse reactions associated with the use of drugs has been carried out for many years and has also been recorded for the radiopharmaceuticals for more than 10 years. The incidence of adverse reactions is very low, it is therefore of importance to collect information from as large an area as possible in order that problems may be identified at an early stage. The definition of adverse reactions may vary from system to system but is in the european system taken to include all unexpected patient reactions. It is essential for the complete coverage that reactions should be reported even if the probability of a relationship between administration of the radiopharmaceutical and the reaction seems small. The reporting of the drug defects have been even more incomplete and no data was therefore given in the first report.
